Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

alarming rise in the incidence of disease, higher numbers of patients with complications and more frequent failures of standard antibiotic therapy.

Tolevamer is designed to bind and neutralize the toxins released by C. difficile that damage the intestine. A non-antibiotic approach has the potential to treat CDAD and reduce the number of disease recurrences, resulting in improved quality of life for the patient and significant savings to the healthcare system.

About the PACT Study

The PACT study, which involved more than 1,100 patients at approximately 300 sites in North America, Europe, and Australia, is the largest of its kind ever to be conducted for CDAD. In this trial, tolevamer was compared to metronidazole and vancomycin. Aside from testing tolevamer's efficacy, this was also the first large, rigorously designed, multi-center clinical study that will compare the efficacy of the current standards of care.

About Clostridium difficile

C. difficile proliferates in the setting of altered normal colonic bacterial flora, most commonly due to the administration of broad-spectrum antibiotics. Once established in the colon, C. difficile produces toxins that disrupt the intestinal lining, causing cell death and inflammation that result in diarrhea and colitis.

Earlier studies have shown that even after successful treatment with the current standard of care, approximately 20 percent of patients experience a recurrence of CDAD potentially requiring repeat hospitalization. In addition, a subset of patients with CDAD develop multiple recurrences of the disease, with symptoms that may persist for years.

About Genzyme One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,000 employees in locations spanning the globe and 2006 revenue
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... Jan. 22, 2015  BiOptix is pleased to announce the ... President of Chemistry and Biochemistry. Scott joins the company after ... and Amgen throughout the course of his nearly 20 ... "Scott is a nationally recognized thought leader in the ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Oct. 21 Laureate Pharma, Inc., a full-service biopharmaceutical ... has signed a new Biopharmaceutical Development and Manufacturing Agreement ... will develop the process to manufacture a unique Fc ... for use in clinical trials. Terms of the manufacturing ...
... Inc. (Amex: UPI ) announced today that it will ... 30, 2009, at the market close on Monday, November 2, ... discuss these results on Monday, November 2, 2009 at 3:30 ... Officer, and Medi Jiwani, Vice President, Chief Financial Officer and ...
Cached Medicine Technology:Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement 2Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009 2
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Board Has Unanimously Recommended That NMHC,s Stockholders Accept ... ... WASHINGTON, NY, March 31 /PRNewswire-FirstCall/ -,SXC Health Solutions Corp. ("SXC") (Nasdaq: ... ("NMHC") (Nasdaq: NMHC ) jointly announced,today that, pursuant to their ...
... - Bikes for meetings, errands, exercise., - Reduce ... Field Museum will add,to its already extensive "green" record ... 2008 - just in time for spring., The ... encourages,employees to bicycle to work by providing showers and ...
... 31 /PRNewswire-FirstCall/,-- Medco Health Solutions, Inc. (NYSE: ... Sweden,s government-operated retail pharmacy authority, Apoteket, to,develop ... system,to improve clinical and financial outcomes for ... Under the agreement, Medco and Apoteket ...
... 31 Ingenuity Systems, the,leading provider of ... that Path Designer, the new pathway publishing ... Best New Product by the scientific community ... San Francisco. Path,Designer enables researchers to create ...
... and Video Available at dietchallenge.usatoday.com, MCLEAN, Va., March ... of its fifth annual USA TODAY Weight-Loss Challenge.,The eight-week ... http://dietchallenge.usatoday.com ., Each week USA TODAY will follow ... changes to their lives, and their waistlines. These,stories range ...
... Study also finds drug-releasing stents appear to work better ... -- In heart attack patients who had angioplasty, the ... certain cardiac measures within 90 minutes after the procedure, ... that patients who received coated stents that released the ...
Cached Medicine News:Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 2Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 3Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 4Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 5Health News:Field Museum Launches Shared Bike Program for Employees 2Health News:Medco Partners to Develop Patient-Safety System for Prescription Drugs in Sweden 2Health News:Medco Partners to Develop Patient-Safety System for Prescription Drugs in Sweden 3Health News:Ingenuity's Path Designer is Selected as Best New Product by Life Science Community at 2008 Molecular Medicine Conference 2Health News:Ingenuity's Path Designer is Selected as Best New Product by Life Science Community at 2008 Molecular Medicine Conference 3Health News:USA TODAY Weight-Loss Challenge Returns For 5th Year With Eight Weeks of Compelling Stories and Online Features 2Health News:USA TODAY Weight-Loss Challenge Returns For 5th Year With Eight Weeks of Compelling Stories and Online Features 3Health News:Anticoagulant Drugs Had Similar Outcomes After Angioplasty 2